BHP87.87-2.49 (-2.76%) ▼|RIO100.08-2.59 (-2.52%) ▼|SCCO192.93+1.25 (+0.65%) ▲|601088.SS41.26-0.60 (-1.43%) ▼|601899.SS29.69-0.74 (-2.43%) ▼|NEM103.79-1.88 (-1.78%) ▼|FCX68.68-0.38 (-0.55%) ▼|GMEXICOB.MX214.21-0.49 (-0.23%) ▼|GLEN.L566.00-17.20 (-2.95%) ▼|AEM166.66-6.33 (-3.66%) ▼|ABX.TO57.08-1.35 (-2.31%) ▼|VALE15.42-0.11 (-0.71%) ▼|1211.HK80.85-1.05 (-1.28%) ▼|ANTO.L4,169.00-92.00 (-2.16%) ▼|WPM122.57-3.28 (-2.61%) ▼|3993.HK18.87-0.56 (-2.88%) ▼|AU90.87-0.05 (-0.06%) ▼|CCJ106.49+0.82 (+0.78%) ▲|FMG.AX19.97-0.35 (-1.72%) ▼|BHP87.87-2.49 (-2.76%) ▼|RIO100.08-2.59 (-2.52%) ▼|SCCO192.93+1.25 (+0.65%) ▲|601088.SS41.26-0.60 (-1.43%) ▼|601899.SS29.69-0.74 (-2.43%) ▼|NEM103.79-1.88 (-1.78%) ▼|FCX68.68-0.38 (-0.55%) ▼|GMEXICOB.MX214.21-0.49 (-0.23%) ▼|GLEN.L566.00-17.20 (-2.95%) ▼|AEM166.66-6.33 (-3.66%) ▼|ABX.TO57.08-1.35 (-2.31%) ▼|VALE15.42-0.11 (-0.71%) ▼|1211.HK80.85-1.05 (-1.28%) ▼|ANTO.L4,169.00-92.00 (-2.16%) ▼|WPM122.57-3.28 (-2.61%) ▼|3993.HK18.87-0.56 (-2.88%) ▼|AU90.87-0.05 (-0.06%) ▼|CCJ106.49+0.82 (+0.78%) ▲|FMG.AX19.97-0.35 (-1.72%) ▼|
31.3 C
New York
Thursday, June 18, 2026

Tag: intellectual property

newssourceFORcompanyinformationcontent1marketreleases

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.

Immunocore to report second quarter 2025 financial results and host call on August 7, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report second quarter financial results, before the US markets open on Thursday, August 7, 2025.

CreateAI to Unveil Innovative AI Products and Timeless Wuxia Classics at ChinaJoy 2025

SHANGHAI, July 30, 2025 /PRNewswire/ -- CreateAI Holdings ("CreateAI" or the "Company") (OTC: TSPH), a leader in applied artificial intelligence technology, will debut major...

Cognex Reports Second Quarter 2025 Results

NATICK, Mass., July 30, 2025 /PRNewswire/ -- Cognex Corporation (NASDAQ: CGNX), the global technology leader in industrial machine vision, today reported financial results for the...

FirstEnergy Announces Second Quarter 2025 Financial Results

Reports second quarter 2025 GAAP earnings of $0.46 per share and Core Earnings (non-GAAP) of $0.52 per share, ahead of plan Reports June 2025...

Modine Reports First Quarter Fiscal 2026 Results

Raising guidance for fiscal 2026 based on improved outlook for data center sales resulting from planned capacity expansion coupled with impact from recent acquisitions RACINE,...

Alkami Announces Second Quarter 2025 Financial Results

PLANO, Texas, July 30, 2025 /PRNewswire/ -- Alkami Technology, Inc. (Nasdaq: ALKT) ("Alkami" or "the Company"), a leading cloud-based digital banking solutions provider for...

eBay Inc. Reports Second Quarter 2025 Results

Revenue of $2.7 billion, up 6% on an as-reported basis and up 4% on an FX-Neutral basisGross Merchandise Volume ("GMV") of $19.5 billion, up...

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

WARREN, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the Company’s significant insider ownership of outstanding common stock, as most recently reported on July 10, 2025, on Form 8-K filed with the Securities and Exchange Commission.

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

– New patent enhances market position in Europe

Stepan Declares Quarterly Dividend

NORTHBROOK, Ill., July 30, 2025 /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported: ...

Stepan Reports Second Quarter 2025 Results

NORTHBROOK, Ill., July 30, 2025 /PRNewswire/ -- Stepan Company (NYSE: SCL) today reported: ...

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

ZYUS Life Sciences Announces Closing of First Tranche of Unit Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ SASKATOON, SK, July 29, 2025 /CNW/ - ZYUS Life Sciences...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsIntellectual property

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers